Treatment‐related neuroendocrine prostate cancer with BRCA2 germline mutation treated with olaparib
IJU Case Reports · 2024-03 · 7 (2) · 115-119
DOI: 10.1002/iju5.12679 ↗Kurz gefasst
Fallbericht in der Zeitschrift IJU Case Reports, online erschienen am 08.12.2023. Verfasst von Riko Ikeda und 5 weiteren Autor:innen. Beteiligte Einrichtung: Department of Urology Saitama Cancer Center Saitama Japan. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 19 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0).
Abstract (Originalsprache)
Introduction
The efficacy of olaparib for treatment‐related neuroendocrine prostate cancer is unknown. Here, we report a case of treatment‐related neuroendocrine prostate cancer with a BRCA2 mutation that was treated with olaparib with 1‐year efficacy. Case presentation A 75‐year‐old man initially diagnosed with prostate adenocarcinoma developed treatment‐related neuroendocrine prostate cancer after 10‐year androgen deprivation therapy. Despite the initial temporary effects of etoposide and carboplatin, the patient experienced prostate bed tumor recurrence 1 year after chemotherapy cessation. FoundationOne® detected a BRCA2 gene mutation, and olaparib was initiated after repeating one chemotherapy course using the same chemotherapeutic agents. The patient received olaparib with sustained tumor regression for 1 year without severe side effects.
Conclusion
Olaparib may be the treatment of choice for treatment‐related neuroendocrine prostate cancer in patients with BRCA mutations.
Schlagwörter
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Department of Urology Saitama Cancer Center Saitama Japan.
- Department of Pathology Saitama Cancer Center Saitama Japan.
- Department of Molecular Diagnosis and Cancer Prevention Saitama Cancer Center Saitama Japan.
ORCID-Profile: Riko Ikeda, Yoh Matsuoka
Zitieren
APA
Ikeda, R., Matsuoka, Y., Inoue, M., Ishikawa, A., Akagi, K., & Kageyama, Y. (2024). Treatment‐related neuroendocrine prostate cancer with BRCA2 germline mutation treated with olaparib. IJU Case Reports, 7(2), 115-119. https://doi.org/10.1002/iju5.12679
Vancouver
Ikeda R, Matsuoka Y, Inoue M, Ishikawa A, Akagi K, Kageyama Y. Treatment‐related neuroendocrine prostate cancer with BRCA2 germline mutation treated with olaparib. IJU Case Reports. 2024;7(2):115-119. doi:10.1002/iju5.12679
BibTeX
@article{Ikeda2024,
author = {Ikeda, Riko and Matsuoka, Yoh and Inoue, Masaharu and Ishikawa, Ayataka and Akagi, Kiwamu and Kageyama, Yukio},
title = {Treatment‐related neuroendocrine prostate cancer with BRCA2 germline mutation treated with olaparib},
journal = {IJU Case Reports},
year = {2024},
volume = {7},
number = {2},
pages = {115--119},
doi = {10.1002/iju5.12679}
}
EUVIMED